| Previous Close | 5.00 |
| Open | 5.02 |
| Volume | 768,987 |
| Avg. Volume (3M) | 603,290 |
| Market Cap | 1,526,845,696 |
| Price / Earnings (TTM) | 21.30 |
| Price / Earnings (Forward) | 10.62 |
| Price / Sales | 2.60 |
| 52 Weeks Range | |
| Earnings Date | 18 Mar 2026 |
| Profit Margin | 16.42% |
| Operating Margin (TTM) | 7.97% |
| Diluted EPS (TTM) | 0.370 |
| Quarterly Revenue Growth (YOY) | 260.00% |
| Quarterly Earnings Growth (YOY) | -65.50% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -148.89 M |
| Levered Free Cash Flow (TTM) | -216.76 M |
| Return on Assets (TTM) | 7.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Alvotech | Bearish | Bearish |
AIStockmoo Score
-0.1
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.13 |
|
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 63.44% |
| % Held by Institutions | 6.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bracebridge Capital, Llc | 30 Sep 2025 | 2,705,304 |
| Littlejohn & Co Llc | 30 Sep 2025 | 1,318,534 |
| Pointstate Capital Lp | 30 Sep 2025 | 1,049,039 |
| Lodbrok Capital Llp | 30 Sep 2025 | 181,587 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Morgan Stanley, 185.71%) | Buy |
| Median | 9.00 (83.67%) | |
| Low | 5.00 (Barclays, 2.04%) | Sell |
| Average | 9.25 (88.78%) | |
| Total | 2 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 6.00 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 09 Dec 2025 | 5.00 (2.04%) | Sell | 5.56 |
| UBS | 18 Nov 2025 | 10.00 (104.08%) | Buy | 5.11 |
| Deutsche Bank | 04 Nov 2025 | 8.00 (63.27%) | Hold | 4.83 |
| Morgan Stanley | 14 Oct 2025 | 14.00 (185.71%) | Buy | 8.50 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |